Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.

ABSTRACT: Many reference biological therapies have now reached or are near to patent expiry, and therefore a number of biosimilars have been or will be developed. The term biosimilar can be defined as a biotherapeutic product that is similar in efficacy, safety and quality to the licensed reference product. Biosimilars may lead to a reduced price and significant cost savings for the health community and hopefully more patients globally will have easier access to biological therapy when indicated. CT-P13, which is a TNF-alfa inhibitor, is the first monoclonal antibody biosimilar being used in clinical practice. The drug is approved for all indications as an innovator product although clinical efficacy has only been demonstrated in rheumatic diseases. Until now the number of patients with inflammatory

SUBMITTER: Jahnsen J 

PROVIDER: S-EPMC4830106 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature